Our indicative theme on Covid-19 Treatment Stocks – which includes companies selling or developing treatments for Covid-19 –  is up by 13% year-to-date, compared to the S&P 500 which is up about 4%. While anti-viral therapeutics are quite complex to develop, companies have largely been adapting existing therapies for Covid treatments while also developing new treatment options. Now the long-term demand for Covid-19 treatments is hazy, considering that the development of a safe and effective vaccine could drastically reduce or possibly eliminate the need for treatments. However, most of the companies on the list have other established products that provide significant downside protection. Below is a bit more about these companies and how they have fared this year.

Regeneron Pharmaceuticals (REGN) recently indicated that its experimental Covid-19 treatment that involves a cocktail of two antibodies was effective in reducing viral loads and improving symptoms in non-hospitalized Covid-19 patients. The stock